Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy
Year: 2026
Type: article
Abstract: Sponsors that hold an IND but not the underlying marketing application face a specific annual reporting problem: some sections of the eCTD annual report hierarchy belong to marketing applications and must be left empty. This article prepares the regulatory operations components of the first annual report for a hypothetical IND held by a follow-on sponsor of a cardiac myosin inhibitor, with a right of reference to an approved application for quality and nonclinical information. The IND supports a completed Phase 1 study (30 entered) and an enrolling Phase 2 study (38 of 120 planned entered). The article reconciles enrollment and demographics, reports blinded pooled adverse events, lists one outstanding item with FDA in the optional log, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and identifies sections that do not apply, and builds a timeline to a March 23, 2027 deadline with Day 46 as the target.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Institution: Northeastern University
Language: English
Topic: Healthcare Regulation
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7237344382
FWCI:
Cites:
Cited by:
Related to:
